|
gptkbp:instanceOf
|
gptkb:chemical_compound
dopamine agonist
|
|
gptkbp:approvalYear
|
2006
|
|
gptkbp:approvedBy
|
gptkb:European_Medicines_Agency
gptkb:U.S._Food_and_Drug_Administration
|
|
gptkbp:ATCCode
|
gptkb:N04BC09
|
|
gptkbp:brand
|
gptkb:Neupro
|
|
gptkbp:CASNumber
|
gptkb:99755-59-6
|
|
gptkbp:category
|
antiparkinsonian agent
phenols
secondary alcohols
naphthalenes
secondary amines
thiophenes
|
|
gptkbp:contraindication
|
hypersensitivity to rotigotine
|
|
gptkbp:discoveredBy
|
gptkb:Schering_AG
|
|
gptkbp:eliminationHalfLife
|
5-7 hours
|
|
gptkbp:excretion
|
urine
feces
|
|
gptkbp:form
|
transdermal patch
|
|
gptkbp:hasMolecularFormula
|
C19H25NOS
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Rotigotine
|
|
gptkbp:IUPACName
|
(6S)-6-(propyl(2-thiophen-2-ylethyl)amino)-5,6,7,8-tetrahydronaphthalen-1-ol
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
dopamine D1 receptor agonist
dopamine D2 receptor agonist
dopamine D3 receptor agonist
|
|
gptkbp:meltingPoint
|
97-98°C
|
|
gptkbp:metabolism
|
hepatic
|
|
gptkbp:pregnancyCategory
|
C (US)
|
|
gptkbp:PubChem_CID
|
gptkb:CHEMBL1201197
DB05271
5311066
4470832
|
|
gptkbp:routeOfAdministration
|
transdermal
|
|
gptkbp:sideEffect
|
gptkb:orthostatic_hypotension
nausea
dizziness
insomnia
drowsiness
hallucinations
application site reaction
|
|
gptkbp:synonym
|
N-0437
|
|
gptkbp:UNII
|
O7J7A4V361
|
|
gptkbp:usedFor
|
gptkb:Parkinson's_disease
gptkb:restless_legs_syndrome
|
|
gptkbp:bfsParent
|
gptkb:CHEMBL37541
gptkb:N04BB
|
|
gptkbp:bfsLayer
|
8
|